X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (515) 515
Publication (50) 50
Newsletter (12) 12
Book Review (8) 8
Book Chapter (5) 5
Newspaper Article (4) 4
Transcript (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (355) 355
index medicus (324) 324
mucopolysaccharidosis (291) 291
enzyme replacement therapy (225) 225
enzymes (222) 222
genetics & heredity (192) 192
male (170) 170
female (145) 145
medicine, research & experimental (145) 145
animals (134) 134
child (127) 127
glycosaminoglycans (110) 110
pediatrics (108) 108
disease (100) 100
child, preschool (94) 94
adolescent (90) 90
health aspects (90) 90
care and treatment (89) 89
treatment outcome (81) 81
enzyme-replacement therapy (80) 80
endocrinology & metabolism (79) 79
bone-marrow-transplantation (76) 76
children (75) 75
adult (69) 69
analysis (69) 69
mice (69) 69
diagnosis (65) 65
lysosomal storage diseases (62) 62
genetics (61) 61
gene therapy (60) 60
biochemistry & molecular biology (57) 57
medicine (57) 57
medicine & public health (57) 57
research (55) 55
mutation (54) 54
enzyme replacement therapy - methods (53) 53
internal medicine (53) 53
young adult (53) 53
disease models, animal (52) 52
maroteaux-lamy-syndrome (52) 52
infant (51) 51
lysosomal storage disease (51) 51
mucopolysaccharidoses (51) 51
biochemistry, general (48) 48
pharmacology & pharmacy (48) 48
article (47) 47
glycosaminoglycans - metabolism (47) 47
transplantation (47) 47
mouse model (46) 46
mucopolysaccharidosis iv - drug therapy (46) 46
biopharmaceutics (45) 45
lysosomal storage disorders (45) 45
patients (44) 44
pharmacology (43) 43
heparan sulfate (42) 42
human genetics (40) 40
hurler-syndrome (40) 40
metabolic diseases (40) 40
biotechnology & applied microbiology (39) 39
recombinant proteins - therapeutic use (39) 39
sulfates (39) 39
brain (38) 38
hematopoietic stem cells (38) 38
phenotype (36) 36
therapy (36) 36
n-acetylgalactosamine 4-sulfatase (35) 35
mucopolysaccharidosis ii - drug therapy (34) 34
mucopolysaccharidoses - therapy (33) 33
genetic therapy (32) 32
glycosaminoglycans - urine (32) 32
medical research (32) 32
clinical trials (31) 31
molecular biology (31) 31
stem-cell transplantation (31) 31
alpha-l-iduronidase (30) 30
mucopolysaccharidosis iva (30) 30
mucopolysaccharidosis vi - drug therapy (30) 30
review (30) 30
stem cells (30) 30
hunter syndrome (29) 29
age (28) 28
metabolic disorders (28) 28
original (28) 28
recombinant proteins - administration & dosage (28) 28
central-nervous-system (27) 27
congenital, hereditary, and neonatal diseases and abnormalities (27) 27
laronidase (27) 27
lysosomal storage (27) 27
mucopolysaccharidosis iv - genetics (27) 27
physiological aspects (27) 27
blood-brain-barrier (26) 26
hematopoietic stem cell transplantation (26) 26
keratan sulfate (26) 26
medicine, experimental (26) 26
usage (26) 26
central nervous system (25) 25
development and progression (25) 25
gene-therapy (25) 25
hunter-syndrome (25) 25
iduronate sulfatase - therapeutic use (25) 25
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (531) 531
French (2) 2
German (2) 2
Italian (1) 1
Polish (1) 1
Russian (1) 1
Spanish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2015, Volume 37, Issue 5, pp. 1012 - 1021.e6
Journal Article
PloS one, ISSN 1932-6203, 2018, Volume 13, Issue 9, p. e0203216
Introduction Mucopolysaccharide diseases are a group of lysosomal storage disorders caused by deficiencies of hydrolase enzymes, leading to pathological... 
HURLER-SYNDROME | MANAGEMENT | COLLAGEN | LARONIDASE | MULTIDISCIPLINARY SCIENCES | PROTEOGLYCAN DEPOSITION | ENDOTHELIAL-CELLS | HEMATOPOIETIC STEM-CELL | BACTERIAL SUPERINFECTION | HEPARAN-SULFATE | ALPHA-L-IDURONIDASE | Tumor Necrosis Factor-alpha - metabolism | Adenoids - pathology | Mucopolysaccharidoses - metabolism | Humans | Tumor Necrosis Factor-alpha - genetics | Child, Preschool | Extracellular Matrix - metabolism | Infant | Interleukin-1alpha - metabolism | Male | Mucopolysaccharidosis III - drug therapy | Mucopolysaccharidoses - pathology | Palatine Tonsil - metabolism | Inflammation Mediators - metabolism | Female | Interleukin-1alpha - genetics | Mucopolysaccharidosis VI - drug therapy | Child | Interleukin-6 - metabolism | Mucopolysaccharidoses - drug therapy | Interleukin-6 - genetics | Adenoids - metabolism | Mucopolysaccharidosis IV - drug therapy | Enzyme Replacement Therapy - methods | Palatine Tonsil - pathology | Mucopolysaccharidosis I - drug therapy | Immunohistochemistry | Enzymes | Usage | Care and treatment | Mucopolysaccharidosis | Genetic aspects | Health aspects | Therapy | Glycosaminoglycans | Disease | Otolaryngology | Lysosomal storage diseases | Biology | Remodeling | Accumulation | Interleukin 6 | Genotype & phenotype | Airway management | Alterations | Laminin | Extracellular matrix | Respiratory tract diseases | Collagen (type IV) | Heparan sulfate | Phenotypes | Biochemical analysis | Cytokines | Hydrolase | Inflammation | Tumor necrosis factor-α | Metabolism | Patients | Substrates | Medicine | Sleep | Hospitals | Collagen | Stem cells | Sampling methods
Journal Article
Journal Article
Journal Article
Pediatric Pulmonology, ISSN 8755-6863, 03/2014, Volume 49, Issue 3, pp. 277 - 284
Background The mucopolysaccharidoses (MPS) comprise a group of inherited lysosomal storage disorders characterized by deficiencies in enzymes catalyzing the... 
glycosaminoglycans | pulmonary function | enzyme replacement therapy | spirometry | mucopolysaccharidoses | MORTALITY | LARONIDASE | EQUATIONS | CHINESE CHILDREN | HONG-KONG | REFERENCE VALUES | RESPIRATORY SYSTEM | PEDIATRICS | Spirometry | Age Factors | Mucopolysaccharidosis IV - complications | Humans | Mucopolysaccharidosis I - physiopathology | Mucopolysaccharidosis VI - complications | Male | Mucopolysaccharidosis III - drug therapy | Lung Diseases - etiology | Forced Expiratory Volume | Young Adult | Mucopolysaccharidosis II - physiopathology | Adult | Female | Mucopolysaccharidoses - complications | Mucopolysaccharidosis VI - drug therapy | Child | Mucopolysaccharidosis VI - physiopathology | Mucopolysaccharidoses - drug therapy | Severity of Illness Index | Mucopolysaccharidoses - physiopathology | Mucopolysaccharidosis III - physiopathology | Treatment Outcome | Lung - physiopathology | Mucopolysaccharidosis IV - drug therapy | Disease Progression | Mucopolysaccharidosis I - complications | Lung Diseases, Obstructive - physiopathology | Mucopolysaccharidosis III - complications | Enzyme Replacement Therapy - methods | Mucopolysaccharidosis II - complications | Mucopolysaccharidosis IV - physiopathology | Mucopolysaccharidosis II - drug therapy | Mucopolysaccharidosis I - drug therapy | Vital Capacity - physiology | Adolescent | Lung Diseases, Obstructive - etiology | Lung Diseases - physiopathology | Respiratory Function Tests | Peak Expiratory Flow Rate | Maximal Midexpiratory Flow Rate | Enzymes | Respiratory tract diseases | Care and treatment | Mucopolysaccharidosis | Glycosaminoglycans | Chemical properties
Journal Article
Journal Article
Drugs, ISSN 0012-6667, 4/2014, Volume 74, Issue 6, pp. 713 - 718
Journal Article
Journal Article